6 results about "Aberrant cell" patented technology

This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a sdAb, wherein the sbAb inhibits the replication of viruses such as Ebola virus and Zika virus in infected cells.

A method for eradicating tumor cells expressing on their surface an MHC-peptide complex comprising a peptide derived from MAGE, the method comprising contacting the cell with at least one immune effector cell through specific interaction of a specific binding molecule for the MHC-peptide complex. Described are bispecific immunoglobulins of which one arm specifically binds to a MHC-MAGE-derived peptide complex associated with aberrant cells, and the other arm specifically recognizes a target associated with immune effector cells. A pharmaceutical composition comprising such bispecific antibody and suitable diluents and / or excipients and a T cell comprising a T-cell receptor or a chimeric antigen receptor recognizing a MHC-peptide complex comprising a peptide derived from MAGE-A is described, as well as a method of producing a T cell comprising introducing into the T-cell nucleic acids encoding an α chain and a ß chain or a chimeric antigen receptor.

The invention relates to the field of binding molecules. In particular, it relates to the field of therapeutic binding molecules for the treatment of diseases involving aberrant cells, such as cancer cells. In particular, it relates to multispecific antibodies that bind an extracellular part of two or more different membrane associated proteins and thereby modulate a biological activity expressed by a cell, and the use of such antibodies in combination therapies.

The disclosure relates to the field of neuregulin-1 (NRG1) fusions, methods for detecting such, identifying or diagnosing patients with such fusions and methods of treatment of a cancer, a tumor or an aberrant cell comprising an NRG1 fusion. Also, it relates to the field of therapeutic (human) compounds for the treatment of subjects with an ErbB-2 / ErbB-3 positive cancer that comprise a NRG1 fusion.

Use of a pyrimidine-based selective cyclin-dependent kinase 2 (CDK2) of structure:or a pharmaceutically acceptable salt thereof or morphic form described herein for the treatment of disorders characterized by aberrant cellular division having amplified cyclin E activation and / or expression or aberrant cellular division disorders, CDK4 / 6 resistance, and / or endocrine therapy resistance, including but not limited to the treatment of tumors and cancers.